Japan Clears First Human Genetic Diagnostic Reagent For Marketing
This article was originally published in PharmAsia News
Executive Summary
Japan's Health Ministry cleared for production the first human genetic diagnostic reagent to be made in the country. Sekisui Medical, a subsidiary of Sekisui Chemical, got approval for the product designed to determine if irinotecan hydrochloride drugs would have severe side effects for cancer patients. Sekisui plans to sell the reagent as a general diagnostic test as early as next spring. Some patients experience severe diaarhea and vomiting after taking the drug. (Click here for more - a subscription may be required
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.